132 related articles for article (PubMed ID: 38604209)
1. Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial.
Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader FA; Chotai S; Pathimagaraj RH; Mohsin M; Salih A; Wang D; Dixit P; Davies JR; Keeble TR; Cosgrove C; Spratt JC; O'Kane PD; De Silva R; Hill JM; Nijjer SS; Sen S; Petraco R; Mikhail GW; Khamis R; Kotecha T; Harrell FE; Kellman P; Francis DP; Howard JP; Cole GD; Shun-Shin MJ; Al-Lamee RK
Lancet; 2024 Apr; 403(10436):1543-1553. PubMed ID: 38604209
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomised, placebo-controlled trial of the coronary sinus Reducer in refractory angina: design and rationale of the ORBITA-COSMIC trial.
Foley MJ; Rajkumar CA; Ahmed-Jushuf F; Simader F; Pathimagaraj RH; Nijjer S; Sen S; Petraco R; Clesham G; Johnson T; Harrell FE; Kellman P; Francis D; Shun-Shin M; Howard J; Cole GD; Al-Lamee R
EuroIntervention; 2024 Feb; 20(3):e216-e223. PubMed ID: 38214677
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial.
Al-Lamee R; Thompson D; Dehbi HM; Sen S; Tang K; Davies J; Keeble T; Mielewczik M; Kaprielian R; Malik IS; Nijjer SS; Petraco R; Cook C; Ahmad Y; Howard J; Baker C; Sharp A; Gerber R; Talwar S; Assomull R; Mayet J; Wensel R; Collier D; Shun-Shin M; Thom SA; Davies JE; Francis DP;
Lancet; 2018 Jan; 391(10115):31-40. PubMed ID: 29103656
[TBL] [Abstract][Full Text] [Related]
4. A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina.
Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Nowbar AN; Simader FA; Davies JR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Gamma R; Clesham G; Williams R; Din J; Nijjer SS; Curzen N; Ruparelia N; Sinha M; Dungu JN; Ganesananthan S; Khamis R; Mughal L; Kinnaird T; Petraco R; Spratt JC; Sen S; Sehmi J; Collier DJ; Sohaib A; Keeble TR; Cole GD; Howard JP; Francis DP; Shun-Shin MJ; Al-Lamee RK;
N Engl J Med; 2023 Dec; 389(25):2319-2330. PubMed ID: 38015442
[TBL] [Abstract][Full Text] [Related]
5. A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.
Nowbar AN; Rajkumar C; Foley M; Ahmed-Jushuf F; Howard JP; Seligman H; Petraco R; Sen S; Nijjer SS; Shun-Shin MJ; Keeble TR; Sohaib A; Collier D; McVeigh P; Harrell FE; Francis DP; Al-Lamee RK
EuroIntervention; 2022 Apr; 17(18):1490-1497. PubMed ID: 35156616
[TBL] [Abstract][Full Text] [Related]
6. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.
Simader FA; Rajkumar CA; Foley MJ; Ahmed-Jushuf F; Chotai S; Bual N; Khokhar A; Gohar A; Lampadakis I; Ganesananthan S; Pathimagaraj RH; Nowbar A; Davies JR; Keeble TR; O'Kane PD; Haworth P; Routledge H; Kotecha T; Spratt JC; Williams R; Nijjer SS; Sen S; Curzen N; Sinha M; Howard JP; Cole G; Harrell FE; Francis DP; Shun-Shin MJ; Al-Lamee RK;
J Am Coll Cardiol; 2024 Jul; 84(1):13-24. PubMed ID: 38759906
[TBL] [Abstract][Full Text] [Related]
7. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Single-Vessel Coronary Artery Disease.
Al-Lamee R; Howard JP; Shun-Shin MJ; Thompson D; Dehbi HM; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik IS; Cook C; Ahmad Y; Sharp ASP; Gerber R; Baker C; Kaprielian R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom SA; Davies JE; Francis DP
Circulation; 2018 Oct; 138(17):1780-1792. PubMed ID: 29789302
[TBL] [Abstract][Full Text] [Related]
8. A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial.
Jolicœur EM; Banai S; Henry TD; Schwartz M; Doucet S; White CJ; Edelman E; Verheye S
Trials; 2013 Feb; 14():46. PubMed ID: 23413981
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.
Ferrari R; Ford I; Fox K; Challeton JP; Correges A; Tendera M; Widimský P; Danchin N;
Lancet; 2020 Sep; 396(10254):830-838. PubMed ID: 32877651
[TBL] [Abstract][Full Text] [Related]
10. Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease: The Stress Echocardiography-Stratified Analysis of ORBITA.
Al-Lamee RK; Shun-Shin MJ; Howard JP; Nowbar AN; Rajkumar C; Thompson D; Sen S; Nijjer S; Petraco R; Davies J; Keeble T; Tang K; Malik I; Bual N; Cook C; Ahmad Y; Seligman H; Sharp ASP; Gerber R; Talwar S; Assomull R; Cole G; Keenan NG; Kanaganayagam G; Sehmi J; Wensel R; Harrell FE; Mayet J; Thom S; Davies JE; Francis DP
Circulation; 2019 Dec; 140(24):1971-1980. PubMed ID: 31707827
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW;
Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
[TBL] [Abstract][Full Text] [Related]
13. Cardiopulmonary exercise testing and efficacy of percutaneous coronary intervention: a substudy of the ORBITA trial.
Ganesananthan S; Rajkumar CA; Foley M; Thompson D; Nowbar AN; Seligman H; Petraco R; Sen S; Nijjer S; Thom SA; Wensel R; Davies J; Francis D; Shun-Shin M; Howard J; Al-Lamee R
Eur Heart J; 2022 Sep; 43(33):3132-3145. PubMed ID: 35639660
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of coronary sinus reducer implantation in patients with chronic total occlusion of the right coronary artery.
Mrak M; Pavšič N; Ponticelli F; Beneduce A; Palmisano A; Guarracini S; Esposito A; Banai S; Žižek D; Giannini F; Bunc M
Kardiol Pol; 2022; 80(1):25-32. PubMed ID: 34643262
[TBL] [Abstract][Full Text] [Related]
15. A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina.
Jolicoeur EM; Verheye S; Henry TD; Joseph L; Doucet S; White CJ; Edelman E; Banai S
Heart; 2021 Jan; 107(1):41-46. PubMed ID: 32719097
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life Assessment in Trials of Revascularization for Chronic Stable Angina: Insights from ORBITA and the Implications of Blinding.
Nowbar AN; Francis DP; Al-Lamee RK
Cardiovasc Drugs Ther; 2022 Oct; 36(5):1011-1018. PubMed ID: 34417901
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
[TBL] [Abstract][Full Text] [Related]
18. Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina: A Single-Center Experience.
Giannini F; Baldetti L; Ponticelli F; Ruparelia N; Mitomo S; Latib A; Montorfano M; Jabbour RJ; Aurelio A; Ferri L; Mangieri A; Regazzoli D; Ancona M; Pagnesi M; Faccini A; Chieffo A; Azzalini L; Carlino M; Colombo A
JACC Cardiovasc Interv; 2018 Apr; 11(8):784-792. PubMed ID: 29673511
[TBL] [Abstract][Full Text] [Related]
19. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
Stone GW; Ellis SG; Gori T; Metzger DC; Stein B; Erickson M; Torzewski J; Williams J; Lawson W; Broderick TM; Kabour A; Piegari G; Cavendish J; Bertolet B; Choi JW; Marx SO; Généreux P; Kereiakes DJ;
Lancet; 2018 Oct; 392(10157):1530-1540. PubMed ID: 30266412
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
